Key Takeaways BSX's international revenues rose, led by 12.1% growth in emerging markets and 15.4% in APAC.BSX's MedSurg strength showed 28% Urology growth and double-digit Endoscopy gains in the United States.BSX's foreign exchange caused a 1.2% Q2 revenue headwind, with tariffs set to impact $100M in 2025.Boston Scientific’s (BSX) second-quarter 2025 performance was driven by its robust expansion of operations across different geographies outside the United States. The company’s impressive growth within t ...